AstraZeneca tightens focus as Crestor generics loom

Country

United Kingdom

With generic competition for the statin Crestor looming, AstraZeneca Plc has taken steps to increase productivity and narrow its investment focus to three therapeutic areas. Going forward, oncology is a priority for the company followed by medicines for respiratory and cardiovascular and metabolic diseases.